Staar Surgical (SR3) Q3 2026 Earnings Report
CH:SR3 Q3 2026 EPS Results
- Actual EPS
- CHF 0.09
- Consensus EPS
- CHF 0.04
- Beat/Miss
- Beat by +CHF 0.05
- One Year Ago EPS
- CHF 0.28
CH:SR3 Q3 2026 Revenue Results
- Actual Revenue
- CHF 68.15M
- Expected Revenue
- CHF 64.33M
- Beat/Miss
- Beat by +CHF 3.82M
- YoY Revenue Growth
- -11.95%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Staar Surgical's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was broadly positive. Management reported record nine-month revenue, strong cash generation, GAAP profitability, growth across China and most international regions, expanding EVO+ and toric adoption, new manufacturing capacity, and progress toward presbyopia trials. The main negatives were lower reported third-quarter revenue and profitability versus the prior-year comparison, reduced gross margin from stated temporary pressures, supply constraints, regional weakness in Japan and South Korea, and limited forward guidance. Highlights significantly outweighed the lowlights.
Management expects fourth quarter gross margin to be above the third quarter and gross margin to continue to improve in 2027, remains on track to meet the $225 million adjusted operating expense target, and expects strong full year GAAP net income and free cash flow; in China, Q4 would be lower from a shape of demand standpoint, yet the company expects to grow versus last year, while stopping short of giving guidance or saying when it might be willing to give guidance for 2027. Each percentage point of yield improvement could generate approximately $750,000 to $1 million in annual incremental gross profit, and first-in-human trials for 2 Collamer-based presbyopia products are expected to begin patient enrollment in the next few months, subject to the receipt of the remaining required regulatory authorizations.
- Record Nine-Month Revenue and ProfitabilitySTAAR delivered record revenue through the first 9 months, generated GAAP net income and free cash flow, and remained debt-free. Management said the performance supports expectations for strong full-year GAAP net income and free cash flow.
- Strong Adjusted Third-Quarter Revenue Growth Excluding China Deferred SalesThird-quarter net sales were $83.4 million, down 12% year over year because the prior-year quarter included $25.9 million of deferred China sales. Excluding that item, third-quarter net sales increased 21% from $68.8 million.
- China Revenue and Unit Shipment GrowthChina net sales grew 31% excluding the $25.9 million of China deferred sales recognized in the prior-year quarter. Distributor unit shipments in China increased 12.4% through the first 9 months, described elsewhere on the call as approximately 12.5%, outpacing the broader Chinese refractive market.
- China Mix Shift Increased Average Selling PricesAll third-quarter China net sales growth came from higher average selling prices due to increased adoption and mix of V5/EVO+ and toric ICLs. Management said higher toric and V5 mix improved ASPs, and V5 demand was stronger than the company was able to supply.
- China Adoption Expanding Beyond Largest HospitalsHundreds of mid-tier hospitals have begun closing the gap with the largest established ICL centers. Management reported growth in public and mid-tier hospitals, higher growth in lower-diopter units than high-diopter units, and continued EVO+ adoption among major hospital systems.
- International Regional GrowthAsia Pacific excluding China grew 4%. EMEA grew 31%, or 51% excluding the Middle East, driven by strong double-digit growth in Spain, Germany, and the U.K. The Americas grew 14%, led by the U.S.
- U.S. Sales Growth Despite Laser Market DeclineThe U.S. recorded its third consecutive quarter with more than $6 million in sales, with double-digit sales growth. This occurred while Refractive Surgery Council data indicated that U.S. laser vision correction procedures declined 5.8% in 2026 versus 2025.
- Structural Shift Toward Lens-Based Vision CorrectionManagement highlighted an ongoing shift from laser-based to lens-based refractive surgery across multiple markets. The company said ICLs are growing while laser volumes are declining in almost every market it tracks.
- Improved Operating Expense PerformanceThird-quarter operating expenses were $53.7 million versus $59.4 million a year ago; the prior-year period included $6 million of restructuring and merger-related costs. Excluding those costs, operating expenses were approximately flat year over year, and the company remains on track for its $225 million adjusted operating expense target.
- Positive GAAP Earnings Excluding Prior-Year Deferred Sales BenefitThird-quarter GAAP net income was $5.6 million, or $0.11 per diluted share. Excluding the prior-year China deferred-sales contribution, the prior-year quarter would have reflected a net loss of $6.3 million, or $0.13 per diluted share, compared with current-quarter GAAP net income.
- Strong Cash Position and Share Repurchase AuthorizationCash, cash equivalents, and available-for-sale investments totaled $206.4 million as of October 2, 2026, up from $181.5 million at the end of the second quarter. The company had no outstanding debt, and the Board authorized a $50 million share repurchase program in September.
- Manufacturing Capacity and Supply Chain ImprovementsAll ICLs destined for China are now manufactured in Switzerland, reducing exposure to tariffs on U.S.-origin products entering China and strengthening supply-chain resilience. A second clean room at Nidau received DEKRA certification, both manufacturing facilities were operating at full capacity, and the company is expanding machining capacity at Monrovia while evaluating automation.
- Yield Improvement OpportunityManagement said each percentage point of manufacturing-yield improvement could generate approximately $750,000 to $1 million in annual incremental gross profit. The company reported that yields are improving after ERP-related issues and are expected to return to normal and increase significantly.
- Presbyopia Pipeline Advancing Toward Human TrialsFirst-in-human trials for two Collamer-based presbyopia products, described as multifocal and aspheric opportunities, are expected to begin patient enrollment in the next few months, subject to remaining regulatory authorizations. The company is targeting a broader product portfolio and stated an ambition to build toward a meaningful product launch every 18 to 24 months.
- Expanded Commercial Leadership and Market OpportunityDavid Bailey returned as Chief Commercial Officer to drive deeper surgeon adoption of EVO, while Andrew Pilon joined as Vice President of Business Development and Pascal Aeschlimann was appointed Vice President of Asia Pacific. U.S. label expansion raised eligibility to age 60, adding approximately 8 million potentially eligible patients, and Brazil's minimum prescription was lowered to minus 0.5 diopters, adding an estimated 26 million potential patients.
- Operational Execution Across Multiple InitiativesDuring the year, the company implemented a new ERP system, completed the move of China-bound ICL manufacturing to Switzerland, ramped production for the EVO+ launch in China, began the clinical trial process for two new lenses, and continued investing in commercial, operational, and product innovation.
CH:SR3 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 24, 2027 | 2026 (Q4) | -0.03- | -0.16 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 0.040.09 | 0.28 | -67.65% (-0.19) | |
| Aug 12, 2026 | 2026 (Q2) | 0.180.13 | -0.28 | 147.20% (+0.41) | |
| May 13, 2026 | 2026 (Q1) | 0.040.34 | -0.42 | 179.30% (+0.76) | |
| Mar 03, 2026 | 2025 (Q4) | 0.15-0.16 | -0.42 | 61.09% (+0.26) | |
| Nov 05, 2025 | 2025 (Q3) | 0.200.28 | 0.21 | 30.77% (+0.07) | |
| Aug 06, 2025 | 2025 (Q2) | -0.46-0.28 | 0.32 | -186.92% (-0.60) | |
| May 07, 2025 | 2025 (Q1) | -0.49-0.42 | 0.09 | -583.18% (-0.51) | |
| Feb 11, 2025 | 2024 (Q4) | -0.02-0.42 | 0.11 | -495.38% (-0.53) | |
| Oct 30, 2024 | 2024 (Q3) | 0.150.21 | 0.25 | -13.33% (-0.03) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
